<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="113.00-MalignantNeoplasticDiseases-Childhood">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>113.00 Cancer - Childhood | Disability | SSA</title>
 
    <!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"true","rua.uprl":"false","rua.cprl":"true","rua.cprf":"false","rua.trans":"SJ-58bf15e4-70d6-4d49-bc49-6919f38410b4","rua.cook":"true","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"true","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n="true"=="true"?1:0,t="cookiepresent",a="im6jsaqx2s43i2inl3ha-f-01ec5f753-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":22,"ak.ipv":4,"ak.proto":"h3","ak.rid":"13d8023c","ak.r":49961,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":62166,"ak.gh":"23.210.6.47","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762483918","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==WcQGWuCfQ2v2Q4tHzNw7D2OEo2R2+o6VGsAftfP8TY3w51iBghKAZy/ZRoFKqDYgVd/AamUgqDADjxAwyVLGXq95musqDggMuvk4TeLTrqlgziou6OcpcTN5jG/ZEXIYRAUBUQuKSqyc2Opj4RHA7mNMYXCES72ocqlJ1luAgIZ2KF7hq4x3ahQ3hIb0r3aZOPqGj9TiKrdbz0uoOX2vtgQuf17FI6r14W2ekWZoeNC/bw1rt83L4W+wYzTlbIlViPWpyPjksBwXu+GuZZLHKrhzxtcEUCgzigiYY72fnUTXbhjb3n22yiQWbn/mVH1RX1ane3ey9geZHNyLnxNt9phvCL+rfAQhjYciY18fNS8Ttl0xo+VXcFBpkze2VuwJcWi+ego68x4T5/Le2r2WaO/O/SyAArEDOzKljmB3K1I=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/113.00-NeoplasticDiseases-Malignant-Childhood.htm#113_00"><meta property="og:title" content="113.00 Cancer - Childhood | Disability | SSA"><meta property="og:description" content="113.00-MalignantNeoplasticDiseases-Childhood"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0" id="Top">Medical/Professional Relations</h2>
        </div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="ChildhoodListings.htm">Listing of Impairments - Child Listings (Part B)</a></li> 
    <li aria-current="page">113.00 Cancer - Childhood</li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

          <h2><span><b> Disability Evaluation Under Social Security<br>
        <br>
        113.00 


Cancer-Childhood<br>
        &nbsp;</b></span></h2>
        
                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
					<article class="cell w-100 m-w-20">

<u><b>Section</b></u><br><br>

	         <p align="left"> 
              <a href="#113_00"><strong>113.00</strong> <br>
              Cancer </a>
            </p><p align="left">
               <a href="#113_01"><b>113.01</b><br>
             Category 
                of
              Impairments,
  Cancer(malignant, neoplastic, diseases)</a><br>
              <br>
                
              <a href="#113_03" title=" 113.03 Malignant Solid Tumors"><b>113.03</b><br>
             Malignant
              solid
              tumors</a><br>
              <br>
                
              <a href="#113_05" title=" 113.05LymphomaexcludingT-cell"><b>113.05</b><br>
            Lymphoma</a><br>
              <br>
              <a href="#113_06" title=" 113.06Leukemia"><b>113.06</b><br>
  Leukemia</a><br>
  <br>
 <a href="#113_09" title=" 113.09Thyroidgland"><b>113.09</b><br>
 Thyroid gland</a><br>
  <br>
  <a href="#113_12" title=" 113.12Retinoblastoma"><b>113.12</b><br>
  Retinoblastoma</a> <br>
  <br>
  <a href="#113_13" title=" 113.13Braintumors">
<b>113.13</b><br>
  Nervous system</a><br>
  <br> 
  <a href="#113_21" title=" 113.21Neuroblastoma"><b>113.21</b><br>
Neuroblastoma</a> <br> <br>

<a href="#113_21" title=" 113.29Malignantmenlanoma"><b>113.29</b><br>
 Malignant melanoma</a>
 
                            </p></article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
							<article class="cell w-100 m-w-80">
                            
      <p id="113_00"><u><b>113.00 Cancer</b></u></p>
      <p align="left" id="113_00A">
          A. <em>What impairments do  these listings cover?</em> We  use these listings to evaluate all
          cancers (malignant neoplastic diseases) except certain cancers associated with human immunodeficiency virus (HIV) infection.
          We use the criteria in <a href="114.00-Immune-Childhood.htm#114_11B" target="_blank" title="114.00 Immune System Disorders - Childhood Page, Section 114.11 - Subsection B">114.11B</a> to evaluate primary central nervous system lymphoma,
          <a href="114.00-Immune-Childhood.htm#114_11C" target="_blank" title="114.00 Immune System Disorders - Childhood Page, Section 114.11 - Subsection C">114.11C</a> to evaluate primary effusion lymphoma,
          and <a href="114.00-Immune-Childhood.htm#114_11E" target="_blank" title="114.00 Immune System Disorders - Childhood Page, Section 114.11 - Subsection E">114.11E</a> to evaluate pulmonary Kaposi sarcoma if you also have HIV infection.
          We evaluate all other cancers associated with HIV infection, for example, Hodgkin lymphoma or non-pulmonary Kaposi sarcoma,
          under this body system or under <a href="114.00-Immune-Childhood.htm#114_11F" target="_blank" title="114.00 Immune System Disorders - Childhood Page, Section 114.11 - Subsection F">114.11F</a>
          - <a href="114.00-Immune-Childhood.htm#114_11I" target="_blank" title="114.00 Immune System Disorders - Childhood Page, Section 114.11 - Subsection I">I</a> in the immune system disorders body system.
      </p>

      <p align="left" id="113_00B">
          B. <em>
              What do we consider when we evaluate cancer
              under these listings?
          </em> We consider factors including:
      </p>
      <p align="left" id="113_00B1">1. Origin of the cancer.</p>
      <p align="left" id="113_00B2">2. Extent of involvement.</p>
      <p align="left" id="113_00B3">3. Duration, frequency, and response to therapy. </p>
      <p>4. Effects of any post-therapeutic residuals.</p>
      <p align="left" id="113_00C">
          C. <em> How do we apply these listings? </em> We apply the criteria
          in a specific listing to a cancer originating from that specific
          site.
      </p>
      <p align="left" id="113_00D">D. <em> What evidence do we need?</em> </p>
      <p align="left" id="113_00D1">
          1.  We need medical evidence that specifies the type, extent, and site of the primary,
          recurrent, or metastatic lesion. In the rare situation in which the primary site
          cannot be identified, we will use evidence documenting the site(s) of metastasis
          to evaluate the impairment under <a href="13.00-NeoplasticDiseases-Malignant-Adult.htm#13_27" title="13.00 Cancer (Malignant Neoplastic Diseases) Page, Section 27" target="_blank">13.27</a> in part A.
      </p>
      <p align="left" id="113_00D2">
          2. For operative procedures,
          including a biopsy or a needle aspiration, we generally need a
          copy of both the:
      </p>
      <p align="left" id="113_00D2a">a. Operative note, and</p>
      <p align="left" id="113_00D2b">b. Pathology report.</p>
      <p id="113_00D3">
          3. When we cannot get these documents, we will accept the summary
          of hospitalization(s) or other medical reports. This evidence should
          include details of the findings at surgery and, whenever appropriate,
          the pathological findings.
      </p>
      <p align="left" id="113_00D4">
          4.
          In some situations we may also need evidence about recurrence,
          persistence, or progression of the cancer, the response to
          therapy, and any significant residuals. (See <a href="#113_00G" title="Section 113.00 - Subsection G">113.00G</a>.)
      </p>
      <p align="left" id="113_00E">
          E. <em>
              When do we need longitudinal
              evidence?
          </em>
      </p>
      <p align="left" id="113_00E1">1. <em>Cancer with distant metastases.</em> Most cancer of childhood consist of a local lesion with metastases to regional lymph nodes and, less often, distant metastases. We generally do not need longitudinal evidence for cancer that has metastasized beyond the regional lymph nodes because  this cancer usually meets the requirements of a listing. Exceptions are for  cancer with distant metastases that we expect to respond to anticancer therapy. For these exceptions, we usually need a longitudinal record of 3 months after therapy starts to determine whether the therapy achieved its intended effect, and whether this effect is likely to persist.  </p>
      <p align="left" id="113_00E2">
          2. <em>Other cancers</em>. When there are no distant metastases,
          many of the listings require that we consider your response to
          initial anticancer therapy; that is, the initial planned
          treatment regimen. This therapy may consist of a single modality
          or a combination of modalities; that is, multimodal therapy (see <a href="#113_00I3" title="Section 113.00 - Subsection I3">113.00I3</a>).
      </p>
      <p align="left" id="113_00E3">
          3. <em>Types of treatment</em>.
          </p><ol type="a">
              <li id="113_00E3a">
                  Whenever the initial planned
                  therapy is a single modality, enough time must pass to allow
                  a determination about whether the therapy will achieve its intended
                  effect. If the treatment fails, the failure will often happen
                  within 6 months after treatment starts, and there will often
                  be a change in the treatment regimen.
              </li>
              <li id="113_00E3b">
                  Whenever the initial planned therapy is multimodal,
                  we usually cannot make a determination about the effectiveness of the therapy until we can determine the effects of all the planned modalities.
                  In some cases, we may need to defer adjudication until we can assess the effectiveness of therapy.
                  However, we do not need to defer adjudication to determine whether the therapy will achieve its intended effect if we can make a fully favorable determination
                  or decision based on the length and effects of therapy,
                  or the residuals of the cancer or therapy (see <a href="#113_00G" title="Section 113.00 - Subsection G">113.00G</a>).
              </li>
          </ol>
      <p></p>

      <p align="left" id="113_00F">
          F. <em>
              How do we evaluate
              impairments that do not meet one of the cancer listings?
          </em>
      </p>
      <p align="left" id="113_00F1">
          1. These listings are only examples of cancer that we consider severe enough to result in marked and
          severe functional limitations. If your impairment(s) does not
          meet the criteria of any of these listings, we must also consider
          whether you have an impairment(s) that meets the criteria of
          a listing in another body system.
      </p>
      <p align="left" id="113_00F2">
          2. If you have a severe medically determinable impairment(s) that does not meet a listing,
          we will determine whether your impairment(s) medically equals a listing.
          (See §§<a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1526.htm" target="_blank" title="Code of Federal Regulations section 404.1526">404.1526</a>
          and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a> of this chapter.)
          If your impairment(s) does not meet or medically equal a listing, we will also consider whether you have an impairment(s) that functionally equals the listings.
          (See §<a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926a.htm" target="_blank" title="Code of Federal Regulations section 416.926a">416.926a</a> of this chapter.)
          We use the rules in §§<a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994a.htm" target="_blank" title="Code of Federal Regulations section 416.99a">416.994a</a> of this chapter when we decide whether you continue to be disabled.
      </p>
      <p align="left" id="113_00G">G. <em> How do we consider the effects of anticancer therapy?</em> </p>
      <p align="left" id="113_00G1">
          1. <em> How we consider the effects of therapy under the listings</em> .
          In many cases, cancers meet listing criteria only if the therapy is not effective and the cancer persists, progresses, or recurs. However, as explained in the following paragraphs, we will not delay adjudication if we can make a fully favorable determination or decision based on the evidence in the case record.
      </p>
      <p align="left" id="113_00G2">2. <em> Effects can vary widely.</em></p>
      <p align="left" id="113_00Ga">a. We consider each case on an individual basis because the therapy and its toxicity may vary widely. We will request a specific description of the therapy, including these items: </p>
      <p align="left" id="113_00G2ai">i. Drugs given.</p>
      <p align="left" id="113_00G2aii">ii. Dosage.</p>
      <p align="left" id="113_00G2aiii">iii. Frequency of drug administration.</p>
      <p align="left" id="113_00G2aiv">iv. Plans for continued drug administration.</p>
      <p align="left" id="113_00G2av">v. Extent of surgery.</p>
      <p align="left" id="113_00G2avi">vi. Schedule and fields of radiation therapy.</p>
      <p align="left" id="113_00Gb">
          b. We will also request a description of the complications or adverse effects of
          therapy, such as the following:
      </p>
      <p align="left" id="113_00Gbi">i. Continuing gastrointestinal symptoms.</p>
      <p align="left" id="113_00Gbii">ii. Persistent weakness.</p>
      <p align="left" id="113_00Gbiii">iii. Neurological complications.</p>
      <p align="left" id="113_00Gbiv">iv. Cardiovascular complications.</p>
      <p align="left" id="113_00Gbv">v. Reactive mental disorders.</p>
      <p align="left" id="113_00G3">3. <em>Effects of therapy may change</em>. The severity of the adverse effects of anticancer therapy may change during treatment; therefore, enough time must pass to allow us to evaluate the therapy's effect. The residual effects of treatment are temporary in most instances; however, on occasion, the effects may be disabling for a consecutive period of at least 12 months. In some situations, very serious adverse effects may interrupt and prolong multimodal anticancer therapy for a continuous period of almost 12 months. In these situations, we may determine there is an expectation that your impairment will preclude you from engaging in any age-appropriate activities for at least 12 &nbsp;months. </p>
      <p align="left" id="113_00G4">
          4. <em> When the initial anticancer therapy is effective</em>.
          We evaluate any post-therapeutic residual impairment(s) not included
          in these listings under the criteria for the affected body system.
          We must consider any complications of therapy. When the residual
          impairment(s) does not meet a listing, we must consider
          whether it medically equals a listing, or, as appropriate, functionally
          equals the listings.
      </p>
      <p align="left" id="113_00H">H. <em> How long do we consider your impairment to be disabling?</em> </p>
      <p align="left" id="113_00H1">
          1. In some listings, we specify that we will consider your impairment to be disabling
          until a particular point in time (for example, until at least 12 months from the date of transplantation). We may consider your impairment to be disabling beyond this point when the medical and other evidence justifies it.
      </p>
      <p align="left" id="113_00H2">2. When a listing does not contain such a specification, we will consider  an impairment(s) that meets or medically equals a listing in this body system  to be disabling until at least 3 years after onset of complete remission. When  the impairment(s) has been in complete remission for at least 3 years, that is,  the original tumor or a recurrence (or relapse) and any metastases have not  been evident for at least 3 years, the impairment(s) will no longer meet or medically  equal the criteria of a listing in this body system.</p>
      <p align="left" id="113_00H3">
          3. Following the appropriate period, we will consider any residuals,
          including residuals of the cancer or therapy (see <a href="#113_00G" title="Section 113.00 - Subsection G">113.00G</a>),
          in determining  whether you are disabled. If you have a recurrence or relapse of your cancer,
          your impairment may meet or medically equal one of the listings in  this body system again.
      </p>
      <p align="left" id="113_00I">
          I.<em>
              What do  we mean by the following terms? &nbsp;<br>
          </em>
      </p>
      <p id="113_00I1">
          1. <em> Anticancer therapy </em> means surgery, radiation, chemotherapy, hormones, immunotherapy, or bone marrow or stem cell transplantation. When we refer to surgery as an anticancer treatment, we mean surgical excision for treatment, not for diagnostic purposes.<br>
      </p>

      <p id="113_00I2">
          2. <em> Metastases </em> means the spread of  cancer cells by blood, lymph, or other body fluid.&nbsp; This term does not include the spread of  cancer cells by direct extension of the cancer to other tissues or organs.<br>
      </p>
      <p id="113_00I3">
          <span>
              3. <em>Multimodal therapy</em> means anticancer therapy that is a combination of at least two types of treatment given in close proximity as a unified whole and usually planned before any treatment has begun. There are three types of treatment modalities: surgery, radiation, and systemic drug therapy (chemotherapy, hormone therapy, and immunotherapy or biological modifier therapy). Examples  of multimodal therapy include: <br>

              </span></p><p id="113_00I3a">a. Surgery followed by chemotherapy or radiation.</p>
              <p id="113_00I3b">b. Chemotherapy followed by surgery.</p>
              <p id="113_00I3c">c. Chemotherapy and concurrent radiation.</p>
          <br>
      <p></p>
      <p align="left" id="113_00I4">4. <em> Persistent </em> means the planned initial anticancer therapy failed to achieve a complete remission of your cancer; that is, your cancer is evident, even if smaller, after the therapy has ended. </p>
      <p align="left" id="113_00I5">5. <em> Progressive </em> means the cancer becomes more extensive after treatment; that is, there is evidence that your cancer is growing after you have completed at least half of your planned initial anticancer therapy. </p>
      <p align="left" id="113_00I6">6. <em> Recurrent, relapse </em> means the cancer that was in complete remission or entirely removed by surgery has returned. </p>
      <p align="left" id="113_00J">
          J. <em>
              Can we establish the existence of a disabling impairment
              prior to the date of the evidence that shows the cancer satisfies
              the criteria of a listing?
          </em> Yes. We will consider factors
          such as:
      </p>
      <p align="left" id="113_00J1">1. The type of cancer and its location.</p>
      <p align="left" id="113_00J2">
          2. The extent of involvement
          when the cancer was first demonstrated.
      </p>
      <p align="left" id="113_00J3">3. Your symptoms.</p>
      <p align="left" id="113_00K">K. <em>How do we evaluate specific cancers?</em> </p>
      <p align="left" id="113_00K1">1. <em> Lymphoma</em>.</p>
      <p align="left" id="113_00K1a">
          a. We provide criteria for evaluating aggressive lymphomas that are
          disseminated or have not responded to anticancer therapy in <a href="#113_05" title="Section 113.05">113.05</a>.
      </p>
      <p align="left" id="113_00K1b">
          b. Lymphoblastic lymphoma is treated with leukemia-based protocols,
          so we will evaluate this type of cancer under <a href="#113_06" title="Section 113.06">113.06</a>.
      </p>
      <p align="left" id="113_00K2">2. <em> Leukemia.</em></p>
      <p align="left" id="113_00K2a">a.<em> Acute leukemia</em>. The initial diagnosis of acute leukemia, including  the accelerated or blast phase of chronic myelogenous (granulocytic) leukemia,  is based upon definitive bone marrow examination. Additional diagnostic  information is based on chromosomal analysis, cytochemical and surface marker  studies on the abnormal cells, or other methods consistent with the prevailing  state of medical knowledge and clinical practice. Recurrent disease must be  documented by peripheral blood, bone marrow, or cerebrospinal fluid  examination, or by testicular biopsy. The initial and follow-up pathology  reports should be included. </p>
      <p align="left" id="113_00K2b">
          b. <em> Chronic myelogenous leukemia (CML)</em>.
          We need a diagnosis of CML based upon documented granulocytosis, including immature forms such as differentiated or undifferentiated myelocytes and myeloblasts,
          and a chromosomal analysis that demonstrates the Philadelphia chromosome. In the absence of a chromosomal analysis,
          or if the Philadelphia chromosome is not present, the diagnosis may be made by other methods consistent with the prevailing state of medical knowledge and clinical practice.
          The requirement of CML in the accelerated or blast phase is met in <a href="#113_06B" title="Section 113.06 - Subsection B">113.06B</a>
          if laboratory findings show the proportion of blast (immature) cells in the peripheral blood or bone marrow is 10 percent or greater.
      </p>
      <p align="left" id="113_00K2c">
          c. <em> Juvenile chronic myelogenous leukemia (JCML)</em>. JCML
          is a rare, Philadelphia-chromosome-negative childhood leukemia
          that is aggressive and clinically similar to acute myelogenous
          leukemia. We evaluate JCML under <a href="#113_06A" title="Section 113.06 - Subsection A">113.06A</a>.
      </p>
      <p align="left" id="113_00K2d">d. <em> Elevated white cell count</em>. In cases of chronic leukemia (either myelogenous or lymphocytic), an elevated white cell count, in itself, is not a factor in determining the severity of the impairment.</p>
      <p align="left" id="113_00K3">
          3. <em> Malignant solid tumors</em>.
          The tumors we consider under <a href="#113_03" title="Section 113.03">113.03</a> include the histiocytosis syndromes except for solitary eosinophilic granuloma.
          We do not evaluate thyroid cancer (see <a href="#113_09" title="Section 113.09">113.09</a>), retinoblastomas (see <a href="#113_12" title="Section 113.12">113.12</a>),
          primary central nervous system (CNS) cancers (see <a href="#113_13" title="Section 113.13">113.13</a>),
          neuroblastomas (see <a href="#113_21" title="Section 113.21">113.21</a>),
          or malignant melanoma (see <a href="#113_29" title="Section 113.29">113.29</a>) under this listing.
      </p>
      <p align="left" id="113_00K4">
          4.<em> Primary central nervous system (CNS) cancers</em>.
          We use the criteria in <a href="#113_13" title="Section 113.13">113.13</a> to evaluate cancers that originate within the CNS
          (that is, brain and spinal cord cancers). <br><br>
          </p><ol type="a">
              <li id="113_00K4a">
                  The CNS cancers listed in <a href="#113_13A" title="Section 113.13 - Subsection A1">113.13A</a> are highly malignant and respond poorly to treatment,
                  and therefore we do not require additional criteria to evaluate them.
                  We do not list pituitary gland cancer (for example, pituitary gland carcinoma) in <a href="#113_13A" title="Section 113.13 - Subsection A1">113.13A</a>,
                  although this CNS cancer is highly malignant and responds poorly to treatment.
                  We evaluate pituitary gland cancer under <a href="#113_13A" title="Section 113.13 - Subsection A">113.13A</a> and do not require additional criteria to evaluate it.
              </li>
              <li id="113_00K4b">
                  We consider a CNS tumor to be malignant if it is classified as Grade II, Grade III,
                  or Grade IV under the World Health Organization (WHO) classification of tumors of the CNS (<em>WHO Classification of Tumours of the Central Nervous System, 2007</em>).
              </li>
              <li id="113_00K4c">
                  We evaluate benign (for example, WHO Grade I)
                  CNS tumors under <a href="111.00-Neurological-Childhood.htm#111_05" title="111.00 Neurological - Childhood Page, Section 111.05" target="_blank">111.05</a>.
                  We evaluate metastasized CNS cancers from non-CNS sites under the primary cancers (see <a href="#113_00C" title="Section 113.00 - Subsection C">113.00C</a>).
                  We evaluate any complications of CNS cancers, such as resultant neurological or psychological impairments,
                  under the criteria for the affected body system.
              </li>
          </ol>
      <p></p>
      <p align="left" id="113_00K5">
          5. <em> Retinoblastoma</em>. The treatment for bilateral retinoblastoma
          usually results in a visual impairment. We will evaluate any
          resulting visual impairment under <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_02" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.02">102.02</a>.
      </p>


      <p align="left" id="113_00K6">
          6. <em>Melanoma</em> We evaluate malignant melanoma that affects the skin (cutaneous melanoma), eye (ocular melanoma),
          or mucosal membranes (mucosal melanoma) under <a href="#113_29" title="Section 113.29">113.29</a>.
          We evaluate melanoma that is not malignant that affects the skin (benign melanocytic tumor)
          under the listings in  <a href="108.00-Skin-Childhood.htm#108_00" target="_blank" title="108.00 Skin Disorders - Childhood Page, Section 108.00">108.00</a> or other affected body systems.
      </p>


      <p align="left" id="113_00L">
          L.  <em>
              How do we evaluate cancer treated by bone marrow or stem cell transplantation,
              including transplantation using stem cells from umbilical cord blood?
          </em>
          Bone marrow or stem cell transplantation is performed for a variety of cancers. We require the transplantation to occur before we evaluate it under these listings.
          We do not need to restrict our determination of the onset of disability to the date of the transplantation
          (<a href="#113_05" title="Section 113.05">113.05</a> or <a href="#113_06" title="Section 113.06">113.06</a>).
          We may be able to establish an earlier onset date of disability due to your transplantation if the evidence in your case record supports such a finding.
      </p>
      <p align="left" id="113_00L1">
           1. <em>
              Acute leukemia (including all types of lymphoblastic lymphoma
              and JCML) or accelerated or blast phase of CML
          </em>. If you
          undergo bone marrow or stem cell transplantation for any of these
          disorders, we will consider you to be disabled until at least
          24 months from the date of diagnosis or relapse, or at least
          12 months from the date of transplantation, whichever is later.
      </p>
      <p align="left" id="113_00L2">
          2. <em> Lymphoma or chronic phase of CML</em>. If you undergo bone
          marrow or stem cell transplantation for any of these disorders,
          we will consider you to be disabled until at least 12 months
          from the date of transplantation.
      </p>
      <p align="left" id="113_00L3">
          3. <em>
              Evaluating disability after the appropriate time period
              has elapsed
          </em>. We consider any residual impairment(s), such
          as complications arising from:
      </p>
      <p align="left" id="113_00L3a">a. Graft-versus-host (GVH) disease.</p>
      <p align="left" id="113_00L3b">b. Immunosuppressant therapy, such as frequent infections.</p>
      <p align="left" id="113_00L3c">c. Significant deterioration of other organ systems.</p>
      <p align="left" id="113_01"><b>113.01 <strong> <i>Category of Impairments, Cancer (Malignant Neoplastic Diseases)</i></strong></b></p>
      <p align="left">
          <span>
              <b>
                  </b></span></p><p id="113_03"><b>113.03<strong><em> Malignant solid tumors</em></strong></b></p><b>
              </b>Consider under a disability:
          
	  <p></p>
      <p align="left" id="113_03A">
          A. For 24 months from the date of initial diagnosis. Thereafter, evaluate any residual
          impairment(s) under the criteria for the affected body system.
      </p>
      <p align="left">OR</p>
      <p align="left" id="113_03B">
          B. For 24 months from the date of recurrence of active disease. Thereafter, evaluate
          any residual impairment(s) under the criteria for the affected body system..
      </p>
      <p align="left" id="113_05">
          <b>
              113.05
          </b> <strong>
              <em>
                  Lymphoma (excluding all types of lymphoblastic
                  lymphoma-- <a href="#113_06" title="Section 113.06">113.06</a>)
              </em>
          </strong>(See <a href="#113_00K1" title="Section 113.00 - Subsection K1">113.00K1</a>)
      </p>
      <p align="left" id="113_05A">A. Non-Hodgkin lymphoma (including Burkitt's and anaplastic large cell), with either 1 or 2:</p>
      <p align="left" id="113_05A1">
          1. Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis.
          Consider under a disability for 24 months from the date of diagnosis. Thereafter,
          evaluate under <a href="#113_05A2" title="Section 113.05 - Subsection A2">113.05A2</a>, or any residual impairment(s) under the criteria for the affected body system.
      </p>
      <p align="left" id="113_05A2">2. Persistent or recurrent following initial anticancer therapy. </p>

      <p align="left">OR</p>
      <p align="left" id="113_05B">B. Hodgkin lymphoma, with either 1 or 2:  </p>
      <p align="left" id="113_05B1">
          1.  Bone marrow, brain, spinal cord, liver, or lung involvement at initial diagnosis. Consider under a disability for 24 months from the date of diagnosis.
          Thereafter, evaluate under <a href="#113_05B2" title="Section 113.05 - Subsection B2">113.05B2</a>,
          or any residual impairment(s) under the criteria for the affected body system.
      </p>
      <p align="left" id="113_05B2">2. Persistent or recurrent following initial anticancer therapy. </p>

      <p align="left">OR</p>
      <p align="left" id="113_05C">
          C. With bone marrow or stem cell transplantation. Consider under a disability until
          at least 12 months from the date of transplantation. Thereafter, evaluate any
          residual impairment(s) under the criteria of the affected body system.
      </p>
      <p align="left">OR  </p>
      <p align="left" id="113_05D">D. Mantle cell lymphoma.</p>

      <p id="113_06">
          <b>113.06</b><em><strong> Leukemia </strong></em>
          (See <a href="#113_00K2" title="Section 113.00 - Subsection K2">113.00K2</a>)
      </p>
      <p align="left" id="113_06A">
          A. Acute leukemia (including all types of lymphoblastic lymphoma and juvenile chronic
          myelogenous leukemia (JCML). Consider under a disability until at least 24 months
          from the date of diagnosis or relapse, or at least 12 months from the date of
          bone marrow or stem cell transplantation, whichever is later. Thereafter, evaluate
          any residual impairment(s) under the criteria for the affected body system.
      </p>
      <p align="left">OR</p>
      <p align="left" id="113_06B">B. Chronic myelogenous leukemia (except JCML), as described in 1 or 2:</p>
      <p align="left" id="113_06B1">
          1. Accelerated or blast phase (see <a href="#113_00K2b" title="Section 113.00 - Subsection K2b">113.00K2b</a>). 
          Consider under a disability until at least 24 months
          from the date of diagnosis or relapse, or at least 12 months from the date of
          bone marrow or stem cell transplantation, whichever is later. Thereafter, evaluate
          any residual impairment(s) under the criteria for the affected body system.
      </p>
      <p align="left" id="113_06B2">2. Chronic phase, as described in a or b:</p>
      <p align="left" id="113_06B2a">
          a. Consider under a disability until at least 12 months from the date of bone marrow
          or stem cell transplantation. Thereafter, evaluate any residual impairment(s)
          under the criteria for the affected body system.
      </p>
      <p align="left" id="113_06B2b">b. Progressive disease following initial anticancer therapy.</p>
      <p align="left" id="113_09">
          <b>
              113.09
          </b><em><strong> Thyroid gland </strong>
          </em>
      </p>
      <p id="113_09A">
          A. Anaplastic (undifferentiated) carcinoma.
      </p>
      <p align="left">OR</p>
      <p align="left" id="113_09B">
          B. Carcinoma with metastases beyond the regional lymph nodes progressive despite
          radioactive iodine therapy.<br>
      </p>
      <p id="113_09C">
          OR<br>
          <br>
          C.&nbsp;  Medullary carcinoma with metastases beyond the regional lymph nodes.
      </p>
      <p align="left" id="113_12">
          <b>
              113.12 </b><em><strong>Retinoblastoma</strong></em>
      </p>
      <p align="left" id="113_12A">A. With extension beyond the orbit.</p>
      <p align="left">OR</p>
      <p align="left" id="113_12B">B. Persistent or recurrent following initial anticancer therapy.</p>
      <p align="left">OR</p>
      <p align="left" id="113_12C">C. With regional or distant metastases.</p>
      <p align="left" id="113_13">
          <b>
          113.13
          </b><em><strong> Nervous system</strong></em>
          (See <a href="#113_00K4" title="Section 113.00 - Subsection K4">113.00K4</a>.) Primary central nervous system (CNS; that is, brain and spinal cord) cancers, as described in A, B, or C:
      </p>
      <p align="left" id="113_13A">A. Glioblastoma multiforme, ependymoblastoma, and diffuse intrinsic brain stem gliomas (see <a href="#113_00K4a" title="Section 113.00 - Subsection K4a">113.00K4a</a>). </p>
      <p align="left" id="113_13B">B. Any Grade III or Grade IV CNS cancer (see <a href="#113_00K4b" title="Section 113.00 - Subsection K4b">113.00K4b</a>), including astrocytomas, sarcomas, and medulloblastoma and other primitive neuroectodermal tumors (PNETs). </p>
      <p align="left" id="113_13C">C. Any primary CNS cancer, as described in 1 or 2:</p>
      <p align="left" id="113_13C1">1. Metastatic.</p>
      <p align="left" id="113_13C2">2. Progressive or recurrent following initial anticancer therapy.</p>

      <p align="left" id="113_21">
          <b>113.21 </b><em><strong> Neuroblastoma</strong></em>
      </p>
      <p align="left" id="113_21A">A. With extension across the midline.</p>
      <p align="left">OR</p>
      <p align="left" id="113_21B">B. With distant metastases.</p>
      <p align="left">OR</p>
      <p align="left" id="113_21C">C. Recurrent.</p>
      <p align="left">OR</p>
      <p align="left" id="113_21D">D. With onset at age 1 year or older. </p>


      <p align="left" id="113_29">
          <b>
              113.29
          </b><em><strong> Malignant melanoma </strong></em> (including skin, ocular, or mucosal melanomas), as described in either A, B, or C:
      </p>

      <p align="left" id="113_29A">A. Recurrent (except an additional primary melanoma at a different site, which is not considered to be recurrent disease) following either 1 or 2: </p>
      <p align="left" id="113_29A1">1. Wide excision (skin melanoma). </p>
      <p align="left" id="113_29A2">2. Enucleation of the eye (ocular melanoma).</p>
      <p align="left">OR </p>
      <p align="left" id="113_29B">B. With metastases as described in 1, 2, or 3:</p>
      <p align="left" id="113_29B1">1. Metastases to one or more clinically apparent nodes; that is, nodes that are detected by imaging studies (excluding lymphoscintigraphy) or by clinical evaluation (palpable).</p>
      <p align="left" id="113_29B2">2. If the nodes are not clinically apparent, with metastases to four or more nodes.</p>
      <p align="left" id="113_29B3">3. Metastases to adjacent skin (satellite lesions) or distant sites (for example, liver, lung, or brain).</p>
      <p align="left">OR</p>
      <p align="left" id="113_29C">C. Mucosal melanoma.</p>


      <p>
          <b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b>
      </p>
      
 </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt on" href="#" title="Back to Top"></a>


</body></html>